Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
about
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsReview of systemic therapies for locally advanced and metastatic rectal cancerIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsIncreased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study.Severe gastrointestinal hemorrhage during targeted therapy for advanced breast carcinoma.Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancerPhase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancerRisk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations.Cardiovascular toxicity of anti-angiogenic drugs.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.Bevacizumab: a review of its use in advanced cancer.Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.Perirenal hematoma in a patient treated with bevacizumab for metastatic colon cancer: A case report.Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.A review of bevacizumab in the treatment of malignant pleural mesothelioma.Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model.[Application of Bevacizumab in Non-small Cell Lung Cancer].Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
P2860
Q26786618-80D9197E-D9D2-4750-B694-4EA6CC457663Q27021105-25B95270-AFD9-48BB-94BB-1A4E4D17B3F9Q28533753-52252157-A094-4CA4-B1DF-4FB09392B096Q30248296-7E24314A-C22A-4FAB-BC22-E8A6220C5450Q33408049-6836DD33-A2F8-4931-AB76-52AC202ACBD1Q33637887-B8AA02F5-E903-4AA6-A014-F04A27EC08EEQ34305959-E5E496A0-E9A5-46D9-B3B1-5E2D60DB0149Q34637564-138A8804-F2C7-44FC-81E2-6174914B8C98Q35584072-5B4D784E-2F54-4593-A131-BEA98D3F424AQ36008274-AC1A7314-83EE-4EE1-B5F9-9BA872D1EFEEQ36742210-3A9EB60A-A7BE-4BC9-BB18-C5DF0F29BB6BQ36751861-CADB0267-90A0-416A-A98A-9635C0A0B8D0Q37052843-250F493E-2CCC-4AB8-86AC-908B80175940Q37206054-1536E600-1265-4422-8B31-505F79D31429Q37960873-A25C4562-A41F-46D6-AFC7-4462D217EF70Q38020234-84FD374C-F77C-4E43-878C-C2EAA4959BA9Q38153444-E27D4D69-5E70-4FC4-9335-C0D1BCE2A482Q38225636-D0C11176-C5D3-4283-9D82-F29D3C5CBB48Q38260176-87784F0F-5491-48B8-9E09-B9A5A13C7202Q38371293-43BED41F-A425-46F0-8972-DC1A617D666BQ38744149-7B9983CC-38DA-4776-954C-9E6E1CBCE75BQ40494844-4C834B4B-237E-4BBB-A449-E8E31AF333C7Q44096551-5A5D8352-4562-4D32-8DEA-8C023093AD07Q44361743-12CB1D3A-BC5A-4BAF-B94B-FAEB05AE9F52Q45128040-759BF836-A51B-47B2-A299-9678E080E626Q47685374-7784CCFB-63D9-4E48-B99D-439AE30FE4B5Q53788954-25DED5F7-B883-409D-B5C7-D11CD4F2E58FQ54121709-968FA9C4-8899-4E51-9055-C3F8890468CAQ54386535-81331590-CE48-485F-A27D-A205C155C33CQ55231488-AD48F27B-B1B9-4992-BCB8-4B1267AE93B6Q55556494-AD088084-54F7-4324-9170-D5AC78B173B3Q58729601-7F781BDD-FDB7-4E70-BF9F-D58A5FAC11C5
P2860
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk of high-grade bleeding in ...... randomized controlled trials.
@ast
Risk of high-grade bleeding in ...... randomized controlled trials.
@en
type
label
Risk of high-grade bleeding in ...... randomized controlled trials.
@ast
Risk of high-grade bleeding in ...... randomized controlled trials.
@en
prefLabel
Risk of high-grade bleeding in ...... randomized controlled trials.
@ast
Risk of high-grade bleeding in ...... randomized controlled trials.
@en
P2093
P2860
P1476
Risk of high-grade bleeding in ...... randomized controlled trials.
@en
P2093
Hai Guang Xin
Jun Xue Wang
Rui Qi Zhang
Wen Sheng Xu
Xiao Feng Hang
P2860
P2888
P304
P356
10.1007/S00228-010-0988-X
P577
2011-01-18T00:00:00Z
P6179
1009266520